We are live on ! Find out more
BWAY

Brainsway

14.15 USD
-0.36
2.48%
At close Updated Sep 4, 4:00 PM EDT
1 day
-2.48%
5 days
-1.87%
1 month
-10.44%
3 months
-0.84%
6 months
13.65%
Year to date
46.63%
1 year
77.1%
5 years
251.12%
10 years
154.95%
 

About: BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Employees: 129

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 46.7%
Neutral 53.3%
Negative 0%
Positive
Zacks Investment Research
8 days ago
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
Positive
Zacks Investment Research
18 days ago
Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway (BWAY) Upgraded to Buy: Here's Why
Positive
MarketBeat
23 days ago
Brainsway Q2 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
Brainsway Q2 Earnings Call Highlights
Neutral
Seeking Alpha
23 days ago
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
24 days ago
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record  s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Positive
Seeking Alpha
1 month ago
BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026 revenue up 35% YoY, a steady 75% gross margin, and expects FY-2026 revenue of $66–68M with adjusted EBITDA growth of 86–100%. Multi-year leasing, accelerated protocols, and expanded provider access are reducing TMS adoption barriers, supporting higher utilization and stickier customer relationships.
BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
Positive
Zacks Investment Research
1 month ago
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
Neutral
Zacks Investment Research
1 month ago
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Neutral
GlobeNewsWire
1 month ago
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care
BrainsWay Announces Strategic Investment in Radial Health, Inc.
Neutral
GlobeNewsWire
1 month ago
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Price charts implemented using Lightweight Charts™